Longevity.Technology’s Post

Last month, Imagine Pharma's Dr. Rita Bottino moderated the "Xenotransplantation’s regulatory road to the clinic" session at the 30th Congress of The Transplantation Society (TTS) in Istanbul. The session included presentations by Wayne John Hawthorne, Efstratios (Stratos) Chatzixiros, and Leo Hans Buhler. The session explored the pioneering efforts that have shaped the landscape of xenotransplantation, from its inception to current breakthroughs. Additionally, the session provided valuable insights into the challenges and opportunities in continuing the registration of clinical xenotransplantation, paving the way for its widespread implementation. #Xenotransplantation #BioTech #RegenerativeMedicine #ImaginePharma #TTS2024

📢 Excited to share our new iteration of the PhoreMost pipeline, advancing our phenotypic screening applications - GlueSEEKER! Watch this space... or should I say, you'll be "GLUEd to your (our) Screens?!?!". No, I most definitely shouldn't, that's a terrible play on words. The technology is cool though! Check it out below! #MolecularGlues #TPD

Exciting research suggests new mechanism for weight loss drugs (Research from Harvard and Stanford Medical Schools) Publication Title: Lac-Phe mediates the anti-obesity effect of metformin Key Findings: Note: CNDP2 is the principal biosynthetic enzyme for Lac-Phe 1) "Metformin is a strong pharmacological inducer of Lac-Phe levels in both mice and humans" (Figure 1) 2) "Metformin increases Lac-Phe levels in a cell autonomous, CNDP2-dependent manner in macrophages and gut epithelial cells, but not in hepatocytes" (Figure 2) 3) "Global CNDP2-KO mice are resistant to metformin-inducible increases in Lac-Phe and also resistant to the anti-obesity effects of metformin therapy." (Figure 5) #pharma #biotech #medicalaffairs #medicalscienceliaison #msl ##clinicalresearch #clinicaltrials #weightloss https://lnkd.in/e2kuf65U

#Microbiome-mediated #drug metabolism along the #gut-#liver axis: Congratulations to first-author Mara Lucchetti and all our collaborators on our new publication describing the interfacing of our #HuMiX gut-on-a-chip model with the Dynamic42 GmbH liver-on-a-chip model. The developed system will allow for new, robust, reproducible and representative experiments related to drug development in the future. Thanks to the following funding agencies for supporting this work: European Commission H2020-MSCA-INTERfaces, Luxembourg National Research Fund (FNR), Fondation Cancer, SNSF Swiss National Science Foundation, Deutsche Forschungsgemeinschaft (DFG) - German Research Foundation & BMBF Innovationsforum: Innovation interaktiv.

Our SPATIALPlex Solutions bring innovative approaches to your biomarker and clinical development programs. Spatially visualizing drug activity with unparalleled precision, Flagship Biosciences supports discovery and target engagement decisions that transcend conventional approaches and enable vivid insights to refine drug efficacy. Learn more… https://hubs.la/Q02rq17H0 #SpatialBiology #SpatialPlexSolutions #DigitalPathology #DrugDevelopment

“Innovation allows us unprecedented achievements, and ultimately, it is a culture: to turn every stone to see how things can be done faster, more efficiently, and with value to the patient” - Dr. Eran Harary At Teva, improving the lives of patients drives our science. Dr. Eran Harary, Head of Global Early-Stage Clinical Development at Teva, recently spoke to Guy Ronen from HaAretz about innovation in drug development through artificial intelligence and advanced technologies, as well as through collaborations with academic and research institutions.  Always with our patients in mind, we continuously look for new ways to fuel innovation in science, medicine and patient care, and aim to expand our future pipeline in our target therapeutic areas of immunology and neuroscience. Click here to read the full article (reprinted with permission): https://lnkd.in/dS6kBapb #Tevapharm #InnovativeMedicines #RandD #ImprovingLives

Publication Alert 📢 Topic : INTOLERANCE OF UNCERTAINTY AND MULTIDIMENSIONAL PERFECTIONISM IN INDIVIDUALS WITH OCD: THE MEDIATING ROLE OF SELF-COMPASSION. Journal: The Journal of Population Therapeutics and Clinical Pharmacology- classified under HEC X category Link: https://lnkd.in/dcbrVQpQ

Today's #biotechnews gives us a peek at what's coming next in medicine. Roche just spent a lot of money scooping up two smaller companies with promising new drugs. One deal could lead to better options for #breastcancerpatients when current meds stop working, while the other could help improve eye treatments for people with vision problems. Targeting specific health issues like this can often help lead to breakthroughs for #biotech companies—and potential investment opportunities for the rest of us! https://loom.ly/jQc4NcY

This study focused on the adrenaline-β2 adrenergic receptor-G protein system to understand how specific receptor residues contribute to efficacy and potency, essential properties in drug design. Using a data science framework integrating pharmacological and structural data, the researchers identified that only 20% of β2AR residues impact pharmacological properties. Ligand-binding residues play a crucial role, and differential contributions to efficacy and potency suggest opportunities for fine-tuning drug responses. The study also unveiled an allosteric network, providing insights into structural changes relevant for pharmacology. This framework holds promise for designing compounds with defined signaling properties in ligand-receptor systems. REFERENCE : https://lnkd.in/gt6fp7gB #news #sciencenews #drugdesign #research ********************************************** Visit us at: https://lnkd.in/g5GYUTpy Follow Us On: Instagram: https://lnkd.in/e9A67gct LinkedIn: https://lnkd.in/gNNCat63 Youtube: https://lnkd.in/diBcNhWE Facebook: https://lnkd.in/gjFh8uKr

The results will be instrumental for shaping future regulations. Are there other routes to promote change in regulation to accelerate acceptance of microphysiological systems by #biotech #pharma?